



Alliance for Clinical Trials in Oncology

Date Friday, May 10, 2019

Loews Chicago O'Hare Hotel

Time 8:00 –10:00 am

Radiation Oncology Committee Meeting Agenda

Chair: Jeff Bogart

Vice-Chair: Joseph Salama

PRIORITY DISCUSSION:

- **PROPOSAL: PHASE I/II TRIAL OF FIVE FRACTION FSRT FOR LARGE BRAIN METASTASES (MELLON)**
- **PROPOSAL : SBRT POST PROSTATECTOMY (KISHAN)**
- **PROPOSAL: HYPOFX RT IN ELDERLY WITH GBM (PALMER)**

NEAR ACTIVATION

- **PHASE III TRIAL OF PCI FOR SMALL CELL LUNG CANCER (SWOG)**
- **PHASE III TRIAL OF IMMUNOTHERAPY FOR LIMITED SMALL CELL LUNG CANCER (LU 005)**

ACTIVE STUDIES

Lung

- **AFT- 16: Induction PDL-1 inhibition Stage III NSCLC** *Urbanic*
- **AFT-07 Veliparib + ChemoRT Stage III NSCLC** *Salama*
- **C 30610: Limited Stage Small Cell Intergroup Trial** – *Bogart*
- **NRG CC003: PCI with or without Hippocampal Avoidance for SCLC** *Grecula*

Breast

- **Alliance A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction** *Poppe*

- **A011202** A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
- **NRG** Oligometastatic Trials *Salama*

CNS

- **CE.7** SRS vs WBRT for Multiple Brain Metastases
- **A221208** Randomized phase II study: Corticosteroids + bevacizumab vs. corticosteroids + placebo (BeSt) for radionecrosis after radiosurgery for brain metastases
- **N0577** Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low grade glioma (CODEL)
- **A071102** A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation

GI

- **A021501** “Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated RT for Borderline Resectable Adenocarcinoma of the Head of the Pancreas”
- **N 1048** A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision (PROSPECT)

GU

- **A031701** PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS (KWOK)
- **PROSTATE CANCER STUDIES (CHEN)**

Other

A091605 Stereotactic body radiotherapy and pembrolizumab in advanced merkel cell carcinoma Chmura

IROC Update